In the context of oncology, liquid biopsies consist of harvesting cancer biomarkers, such as circulating tumor cells, tumor-derived cell-free DNA, and extracellular vesicles, from bodily fluids. These biomarkers provide a source of clinically actionable molecular information that can enable precision medicine. Herein, we review technologies for the molecular profiling of liquid biopsy markers with special emphasis on the analysis of low abundant markers from mixed populations.
From the *Department of Chemistry and †Center of BioModular Multiscale Systems for Precision Medicine, The University of Kansas, Lawrence, KS; ‡Department of Biomedical Engineering, The University of North Carolina, Chapel Hill, NC; §BioEngineering Program and ∥Department of Mechanical Engineering, The University of Kansas, Lawrence, KS; and ¶Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea.
C.D.M.C. and J.M.J. contributed equally to this work.
This study received financial support from the National Institutes of Health (NIBIB P41-EB020594; IMAT R21-CA173279).
The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Reprints: Małgorzata A. Witek, PhD, 259 Multidisciplinary Research Bldg, 2030 Becker Dr, Lawrence, KS 66047. E-mail: email@example.com; or Steven A. Soper, PhD, 220C Multidisciplinary Research Bldg, 2030 Becker Dr, Lawrence, KS 66047. E-mail: firstname.lastname@example.org.